Sonoma BioTherapeutics is a biotechnology company that develops therapies for chronic pain and other neurological disorders. The company's lead product candidate, ST-001 nanoFenretinide, is a small molecule drug that targets the TRPV1 receptor to reduce pain and inflammation. Sonoma BioTherapeutics is also developing other drug candidates for pain and neurodegenerative diseases. The company was founded in 2018 and is based in South San Francisco, California.